関連レポート

がん診断用AI（人工知能）の世界市場：2031年予測

サイト内検索

お探しの資料等をキーワード検索できます。英語検索も有効です。

出版元：Transparency Market Research 　 出版元について

発行年：2023年12月

定価 ：Single User License(1名様ライセンス)US$5,795(米国ドル)/Multi User License(5名様)$8,795 /Enterprise License $11,705

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

ご請求は円換算（お見積り日TTSレート）となります。

納品形態：PDF by Email

当調査レポートは英文178ページになります。

商品コード：TMR151

【レポート紹介】

頭頸部がん治療の世界市場規模は2022年で16億ドル、2031年に29億ドル、市場の平均年成長率は6.8%になると見込まれています。

当レポートでは、頭頸部がんの市場予測-2031年、各種セグメント別市場分析(薬剤クラス別、販売経路別、国地域別)、パイプライン分析、市場シェア分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

■頭頸部がん治療の世界市場予測2017-2031年

・市場規模(US$)

■薬剤クラス別、市場-2031年

EGFR阻害剤
分裂阻害剤
抗PD-1モノクローナル抗体
その他
※(市場規模US$)

■販売経路別、市場-2031年

病院薬局
小売薬局
Eコマース
※(市場規模US$)

■主要国地域別市場-2031年

北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・ASEAN
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析

市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響分析
競合状況
市場シェア分析
SWOT分析

■頭頸部がん治療の主要企業プロフィール動向

Sanofi
Pfizer
Eli Lilly and Company
F. Hoffmann-La Roche
AstraZeneca
Merck KgaA
Bayer AG
Bristol-Myers Squibb Company
Bayer AG
Galera
Fresenius Kabi
Teva Pharmaceuticals

（全178頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

1. Executive Summary

    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology
3. Executive Summary: Global Head and Neck Cancer Market
4. Market Overview

    4.1. Market Segmentation
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Head and Neck Cancer Market Analysis and Forecasts, 2017-2031

5. Key Insights

    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry

6. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class

    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2017–2031
        6.3.1. EGFR Inhibitors
        6.3.2. Mitotic Inhibitors
        6.3.3. Anti-PD-1 Monoclonal Antibodies
        6.3.4. Others
    6.4. Market Attractiveness, by Drug Class

7. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Distribution Channel, 2017–2031
        7.3.1. Hospitals Pharmacies
        7.3.2. Retail Pharmacies
        7.3.3. E-commerce
    7.4. Market Attractiveness, by Distribution Channel

8. Global Head and Neck Cancer Market Analysis and Forecast, by Region

    8.1. Key Findings
    8.2. Market Value Forecast, by Region, 2017–2031
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness, by Region

9. North America Head and Neck Cancer Market Analysis and Forecast

    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by Drug Class, 2017–2031
        9.2.1. EGFR Inhibitors
        9.2.2. Mitotic Inhibitors
        9.2.3. Anti-PD-1 Monoclonal Antibodies
        9.2.4. Others
    9.3. Market Value Forecast, by Distribution Channel, 2017–2031
        9.3.1. Hospitals Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. E-commerce
    9.4. Market Value Forecast, by Country, 2017–2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Drug Class
        9.5.2. By Distribution Channel
        9.5.3. By Country

10. Europe Head and Neck Cancer Market Analysis and Forecast

    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Class, 2017–2031
        10.2.1. EGFR Inhibitors
        10.2.2. Mitotic Inhibitors
        10.2.3. Anti-PD-1 Monoclonal Antibodies
        10.2.4. Others
    10.3. Market Value Forecast, by Distribution Channel, 2017–2031
        10.3.1. Hospitals Pharmacies
        10.3.2. Retail Pharmacies
        10.3.3. E-commerce
    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Drug Class
        10.5.2. By Distribution Channel
        10.5.3. By Country/Sub-region

11. Asia Pacific Head and Neck Cancer Market Analysis and Forecast

    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017–2031
        11.2.1. EGFR Inhibitors
        11.2.2. Mitotic Inhibitors
        11.2.3. Anti-PD-1 Monoclonal Antibodies
        11.2.4. Others
    11.3. Market Value Forecast, by Distribution Channel, 2017–2031
        11.3.1. Hospitals Pharmacies
        11.3.2. Retail Pharmacies
        11.3.3. E-commerce
    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Drug Class
        11.5.2. By Distribution Channel
        11.5.3. By Country/Sub-region

12. Latin America Head and Neck Cancer Market Analysis and Forecast

    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017–2031
        12.2.1. EGFR Inhibitors
        12.2.2. Mitotic Inhibitors
        12.2.3. Anti-PD-1 Monoclonal Antibodies
        12.2.4. Others
    12.3. Market Value Forecast, by Distribution Channel, 2017–2031
        12.3.1. Hospitals Pharmacies
        12.3.2. Retail Pharmacies
        12.3.3. E-commerce
    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Drug Class
        12.5.2. By Distribution Channel
        12.5.3. By Country/Sub-region

13. Middle East & Africa Head and Neck Cancer Market Analysis and Forecast

    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017–2031
        13.2.1. EGFR Inhibitors
        13.2.2. Mitotic Inhibitors
        13.2.3. Anti-PD-1 Monoclonal Antibodies
        13.2.4. Others
    13.3. Market Value Forecast, by Distribution Channel, 2017–2031
        13.3.1. Hospitals Pharmacies
        13.3.2. Retail Pharmacies
        13.3.3. E-commerce
    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Drug Class
        13.5.2. By Distribution Channel
        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    14.2. Market Share Analysis, by Company (2022)
    14.3. Company Profiles
        14.3.1. Sanofi
            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.1.2. Product Portfolio
            14.3.1.3. Financial Overview
            14.3.1.4. SWOT Analysis
            14.3.1.5. Strategic Overview
        14.3.2. Pfizer
            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.2.2. Product Portfolio
            14.3.2.3. Financial Overview
            14.3.2.4. SWOT Analysis
            14.3.2.5. Strategic Overview
        14.3.3. Eli Lilly and Company
            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.3.2. Product Portfolio
            14.3.3.3. Financial Overview
            14.3.3.4. SWOT Analysis
            14.3.3.5. Strategic Overview
        14.3.4. F. Hoffman-La Roche
            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.4.2. Product Portfolio
            14.3.4.3. Financial Overview
            14.3.4.4. SWOT Analysis
            14.3.4.5. Strategic Overview
        14.3.5. AstraZeneca
            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.5.2. Product Portfolio
            14.3.5.3. Financial Overview
            14.3.5.4. SWOT Analysis
            14.3.5.5. Strategic Overview
        14.3.6. Merck KgaA
            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.6.2. Product Portfolio
            14.3.6.3. Financial Overview
            14.3.6.4. SWOT Analysis
            14.3.6.5. Strategic Overview
        14.3.7. Bayer AG
            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.7.2. Product Portfolio
            14.3.7.3. Financial Overview
            14.3.7.4. SWOT Analysis
            14.3.7.5. Strategic Overview
        14.3.8. Bristol-Myers Squibb Company
            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.8.2. Product Portfolio
            14.3.8.3. Financial Overview
            14.3.8.4. SWOT Analysis
            14.3.8.5. Strategic Overview
        14.3.9. Galera
            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.9.2. Product Portfolio
            14.3.9.3. Financial Overview
            14.3.9.4. SWOT Analysis
            14.3.9.5. Strategic Overview
        14.3.10. Fresenius Kabi
            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.10.2. Product Portfolio
            14.3.10.3. Financial Overview
            14.3.10.4. SWOT Analysis
            14.3.10.5. Strategic Overview
        14.3.11. Teva Pharmaceuticals
            14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.11.2. Product Portfolio
            14.3.11.3. Financial Overview
            14.3.11.4. SWOT Analysis
            14.3.11.5. Strategic Overview

List of Tables

Table 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 2: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 3: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 4: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 5: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 6: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 7: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 8: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 9: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

Table 10: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 12: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

Table 16: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 18: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

List of Figures

Figure 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

Figure 2: Global Head and Neck Cancer Market Value Share, by Drug Class, 2022

Figure 3: Global Head and Neck Cancer Market Value Share, by Distribution Channel, 2022

Figure 4: Global Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 5: Global Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 6: Global Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 7: Global Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 8: Global Head and Neck Cancer Market Value Share Analysis, by Region, 2022 and 2031

Figure 9: Global Head and Neck Cancer Market Attractiveness Analysis, by Region, 2023–2031

Figure 10: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

Figure 11: North America Head and Neck Cancer Market Value Share Analysis, by Country, 2022 and 2031

Figure 12: North America Head and Neck Cancer Market Attractiveness Analysis, by Country, 2023–2031

Figure 13: North America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 14: North America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 15: North America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 16: North America Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 17: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

Figure 18: Europe Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 19: Europe Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 20: Europe Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 21: Europe America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 22: Europe Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 23: Europe Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 24: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

Figure 25: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 26: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 27: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 28: Asia Pacific America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 29: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 30: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 31: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

Figure 32: Latin America Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 33: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 34: Latin America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 35: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 36: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 37: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Middle East & Africa America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022–2031

Figure 39: Middle East & Africa America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 40: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 41: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 42: Global Head and Neck Cancer Market Share Analysis, by Company (2022)